Page last updated: 2024-08-21

pyrazines and atrasentan

pyrazines has been researched along with atrasentan in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Nelson, JB; Smith, MR	1
Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H	1

Reviews

1 review(s) available for pyrazines and atrasentan

Article	Year
Future therapies in hormone-refractory prostate cancer. Urology, 2005, Volume: 65, Issue:5 Suppl Topics: Antibodies, Monoclonal; Atrasentan; Boronic Acids; Bortezomib; Diphosphonates; DNA, Antisense; Forecasting; Humans; Immunotherapy; Male; Prostatic Neoplasms; Pyrazines; Pyrrolidines; Receptors, Growth Factor; Thalidomide	2005

Other Studies

1 other study(ies) available for pyrazines and atrasentan

Article	Year
[Molecular-targeted therapy for hormone-refractory prostate cancer]. Hinyokika kiyo. Acta urologica Japonica, 2006, Volume: 52, Issue:6 Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D	2006

Article

Year

[Molecular-targeted therapy for hormone-refractory prostate cancer].

Hinyokika kiyo. Acta urologica Japonica, 2006, Volume: 52, Issue:6

Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D

2006